FDA – Page 53 – Policy & Medicine

FDA Five Year Plan on Risk Benefits Framework

Proposed FDA Guidance on Financial Disclosure and the Physician Payment Sunshine Regulations – Divergent Paths and Duplicated Efforts

FDA-CDER Solicits Comments on Issues in Product Development Including Research and Promotion

FDA: Enhancing Benefit-Risk Assessment in Regulatory Decision Making

FDA Outlines Generic Safety and Efficacy

FDA Drug Shortages: Fundamental Problem is the Inability for the Market to Observe and Reward Quality

FDA: Partnerships to Accelerate Medical Product Development

Emerging Issues in Food and Drug Law: A National Conference for Lawyers, Policy-Makers, and Corporate Leaders

FDA Reorganizing Office of Prescription Drug Promotion

Court Upholds InterMune Executive Conviction on Misleading Speech